Down syndrome (DS) is the most common genetic cause of intellectual disability, resulting from trisomy of chromosome 21. The main feature of DS neuropathology includes early onset of Alzheimer’s disease (AD), with deposition of senile plaques and tangles. We hypothesized that apoptosis may be activated in the presence of AD neuropathology in DS, thus we measured proteins associated with upstream and downstream pathways of p53 in the frontal cortex from DS cases with and without AD pathology and from Ts65Dn mice, at different ages. We observed increased acetylation and phosphorylation of p53, coupled to reduced MDM2/p53 complex level and lower levels of SIRT1. Activation of p53 was associated with a number of targets (BAX, PARP1, caspase-3, p21, heat shock proteins, and PGC1α) that were modulated in both DS and DS/AD compared with age-matched controls. In particular, the most relevant changes (increased p-p53 and acetyl-p53 and reduced formation of MDM2/p53 complex) were found to be modified only in the presence of AD pathology in DS. In addition, a similar pattern of alterations in the p53 pathway was found in Ts65Dn mice. These results suggest that p53 may integrate different signals, which can result in a pro-apoptotic-phenotype contributing to AD neuropathology in people with DS.
GlassonEJ, SullivanSG, HussainR, PettersonBA, MontgomeryPD, BittlesAH (2002) The changing survival profile of people with Down’s syndrome: Implications for genetic counselling. Clin Genet62, 390–393.
2.
RuedaN, FlorezJ, Martinez-CueC (2013) Apoptosis in Down’s syndrome: Lessons from studies of human and mouse models. Apoptosis18, 121–134.
3.
GoldenJA, HymanBT (1994) Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol53, 513–520.
4.
GuidiS, BonasoniP, CeccarelliC, SantiniD, GualtieriF, CianiE, BartesaghiR (2008) Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol18, 180–197.
5.
ContestabileA, FilaT, CeccarelliC, BonasoniP, BonapaceL, SantiniD, BartesaghiR, CianiE (2007) Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus17, 665–678.
6.
ContestabileA, FilaT, CappelliniA, BartesaghiR, CianiE (2009) Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. Cell Prolif42, 171–181.
7.
RuedaN, MostanyR, PazosA, FlorezJ, Martinez-CueC (2005) Cell proliferation is reduced in the dentate gyrus of aged but not young Ts65Dn mice, a model of Down syndrome. Neurosci Lett380, 197–201.
8.
CulmseeC, MattsonMP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun331, 761–777.
9.
CheclerF, Alves da CostaC (2014) p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther142, 99–113.
RufiniA, TucciP, CelardoI, MelinoG (2013) Senescence and aging: The critical roles of p53. Oncogene32, 5129–5143.
12.
FioriniA, SultanaR, BaroneE, CeniniG, PerluigiM, MancusoC, CaiJ, KleinJB, ClairDSt, ButterfieldDA (2012) Lack of p53 affects the expression of several brain mitochondrial proteins: Insights from proteomics into important pathways regulated by p53. PLoS One7, e49846.
MollUM, PetrenkoO (2003) The MDM2-p53 interaction. Mol Cancer Res1, 1001–1008.
15.
LiuB, ChenY, ClairDKSt (2008) ROS and p53: A versatile partnership. Free Radic Biol Med44, 1529–1535.
16.
BrooksCL, GuW (2011) The impact of acetylation and deacetylation on the p53 pathway. Protein Cell2, 456–462.
17.
NakamuraS, RothJA, MukhopadhyayT (2000) Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol20, 9391–9398.
18.
GuW, RoederRG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell90, 595–606.
19.
LuoJ, LiM, TangY, LaszkowskaM, RoederRG, GuW (2004) Acetylation of p53 augments its site-specific DNA binding both in vivo and in vitro. Proc Natl Acad Sci U S A101, 2259–2264.
20.
CardaciS, FilomeniG, RotilioG, CirioloMR (2008) Reactive oxygen species mediate p53 activation and apoptosis induced by sodium nitroprusside in SH-SY5Y cells. Mol Pharmacol74, 1234–1245.
21.
ShiY, NikulenkovF, Zawacka-PankauJ, LiH, GabdoullineR, XuJ, ErikssonS, HedstromE, IssaevaN, KelA, ArnerES, SelivanovaG (2014) ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ21, 612–623.
22.
Di DomenicoF, PupoG, TramutolaA, GiorgiA, SchininaME, CocciaR, HeadE, ButterfieldDA, PerluigiM (2014) Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: Clues for understanding the develoment of Alzheimer disease. Free Radic Biol Med71, 270–280.
23.
PerluigiM, Di DomenicoF, ButtterfieldDA (2014) Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. Proteomics Clin Appl8, 73–85.
24.
ButterfieldDA, Di DomenicoF, SwomleyAM, HeadE, PerluigiM (2014) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: Overlaps in Down’s syndrome and Alzheimer’s disease brain. Biochem J463, 177–189.
25.
CeniniG, DowlingAL, BeckettTL, BaroneE, MancusoC, MurphyMP, LevineH3rd, LottIT, SchmittFA, ButterfieldDA, HeadE (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta1822, 130–138.
26.
Di DomenicoF, CocciaR, CoccioloA, MurphyMP, CeniniG, HeadE, ButterfieldDA, GiorgiA, SchininaME, MancusoC, CiniC, PerluigiM (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer’s disease neuropathology: Redox proteomics analysis of human brain. Biochim Biophys Acta1832, 1249–1259.
27.
PerluigiM, PupoG, TramutolaA, CiniC, CocciaR, BaroneE, HeadE, ButterfieldDA, Di DomenicoF (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta1842, 1144–1153.
28.
ReinholdtLG, DingY, GilbertGJ, CzechanskiA, SolzakJP, RoperRJ, JohnsonMT, DonahueLR, LutzC, DavissonMT (2011) Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm Genome22, 685–691.
29.
SilvaAR, SantosAC, FarfelJM, GrinbergLT, FerrettiRE, CamposAH, CunhaIW, BegnamiMD, RochaRM, CarraroDM, de Braganca PereiraCA, Jacob-FilhoW, BrentaniH (2014) Repair of oxidative DNA damage, cell-cycle regulation and neuronal death may influence the clinical manifestation of Alzheimer’s disease. PLoS One9, e99897
30.
BrooksCL, GuW (2010) New insights into p53 activation. Cell Res20, 614–621.
31.
KruseJP, GuW (2009) Modes of p53 regulation. Cell137, 609–622.
32.
van LeeuwenI, LainS (2009) Sirtuins and p53. Adv Cancer Res102, 171–195.
33.
NorthBJ, MarshallBL, BorraMT, DenuJM, VerdinE (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell11, 437–444.
34.
HoffmannG, BreitenbucherF, SchulerM, Ehrenhofer-MurrayAE (2014) A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J Biol Chem289, 5208–5216.
35.
LanniC, UbertiD, RacchiM, GovoniS, MemoM (2007) Unfolded p53: A potential biomarker for Alzheimer’s disease. J Alzheimers Dis12, 93–99.
36.
ChildsBG, BakerDJ, KirklandJL, CampisiJ, van DeursenJM (2014) Senescence and apoptosis: Dueling or complementary cell fates?. EMBO Rep15, 1139–1153.
37.
QinW, HaroutunianV, KatselP, CardozoCP, HoL, BuxbaumJD, PasinettiGM (2009) PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol66, 352–361.
LottIT, HeadE (2001) Down syndrome and Alzheimer’s disease: A link between development and aging. Ment Retard Dev Disabil Res Rev7, 172–178.
40.
BusciglioJ, YanknerBA (1995) Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro. Nature378, 776–779.
41.
FriedlanderRM (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med348, 1365–1375.
42.
StadelmannC, DeckwerthTL, SrinivasanA, BancherC, BruckW, JellingerK, LassmannH (1999) Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer’s disease. Evidence for apoptotic cell death. Am J Pathol155, 1459–1466.
43.
EspositoE, CuzzocreaS (2010) New therapeutic strategy for Parkinson’s and Alzheimer’s disease. Curr Med Chem17, 2764–2774.
44.
CeniniG, SultanaR, MemoM, ButterfieldDA (2008) Elevated levels of pro-apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer’s disease. J Cell Mol Med12, 987–994.
45.
Di DomenicoF, CeniniG, SultanaR, PerluigiM, UbertiD, MemoM, ButterfieldDA (2009) Glutathionylation of the pro-apoptotic protein p53 in Alzheimer’s disease brain: Imlications for AD pathogenesis. Neurochem Res34, 727–733.
46.
CeniniG, SultanaR, MemoM, ButterfieldDA (2008) Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease. Free Radic Biol Med45, 81–85.
47.
de la MonteSM (1999) Molecular abnormalities of the brain in Down syndrome: Relevance to Alzheimer’s neurodegeneration. J Neural Transm Suppl57, 1–19.
48.
BarlevNA, LiuL, ChehabNH, MansfieldK, HarrisKG, HalazonetisTD, BergerSL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell8, 1243–1254.
49.
LiuG, ChenX (2006) Regulation of the p53 transcriptional activity. J Cell Biochem97, 448–458.
50.
WangDB, KinoshitaC, KinoshitaY, MorrisonRS (2014) p53 and mitochondrial function in neurons. Biochim Biophys Acta1842, 1186–1197.
51.
ThompsonT, TovarC, YangH, CarvajalD, VuBT, XuQ, WahlGM, HeimbrookDC, VassilevLT (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem279, 53015–53022.
52.
DonmezG, OuteiroTF (2013) SIRT1 and SIRT2: Emerging targets in neurodegeneration. EMBO Mol Med5, 344–352.
53.
MinSW, ChoSH, ZhouY, SchroederS, HaroutunianV, SeeleyWW, HuangEJ, ShenY, MasliahE, MukherjeeC, MeyersD, ColePA, OttM, GanL (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron67, 953–966.
54.
LuoJ, NikolaevAY, ImaiS, ChenD, SuF, ShilohA, GuarenteL, GuW (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell107, 137–148.
55.
CoppeJP, PatilCK, RodierF, KrtolicaA, BeausejourCM, ParrinelloS, HodgsonJG, ChinK, DesprezPY, CampisiJ (2010) A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS One5, e9188.
56.
HelgueraP, PelsmanA, PiginoG, WolvetangE, HeadE, BusciglioJ (2005) ets-2 promotes the activation of a mitochondrial death pathway in Down’s syndrome neurons. J Neurosci25, 2295–2303.
57.
SeidlR, CairnsN, LubecG (2001) The brain in Down syndrome. J Neural Transm Suppl247–261.
58.
SalemiM, BaroneC, RomanoC, RidolfoF, GulottaE, ScavuzzoC, SalluzzoMG, GiambirtoneM, CaraciF, RomanoC, BoscoP (2011) Differential expression of PARP1 mRNA in leucocytes of patients with Down’s syndrome. J Genet90, 469–472.
59.
AndersonAJ, StoltznerS, LaiF, SuJ, NixonRA (2000) Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL. Neurobiol Aging21, 511–524.
AustinS, St-PierreJ (2012) PGC1alpha and mitochondrial metabolism–emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci125, 4963–4971.
62.
HandschinC, SpiegelmanBM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev27, 728–735.
63.
PerluigiM, ButterfieldDA (2012) Oxidative stress and Down syndrome: A route toward alzheimer-like dementia. Curr Gerontol Geriatr Res2012, 724904.
64.
LottIT, HeadE, DoranE, BusciglioJ (2006) Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res3, 521–528.
65.
Di DomenicoF, PupoG, MancusoC, BaroneE, PaoliniF, ArenaA, BlarzinoC, SchmittFA, HeadE, ButterfieldDA, PerluigiM (2015) Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: Insights for transition to Alzheimer’s disease. J Alzheimers Dis44, 1107–1120.
66.
GuedjF, PenningsJL, FerresMA, GrahamLC, WickHC, MiczekKA, SlonimDK, BianchiDW (2015) The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome. Am J Med Genet A167A, 1993–2008.
67.
GuedjF, PenningsJL, WickHC, BianchiDW (2015) Analysis of adult cerebral cortex and hippocampus transcriptomes reveals unique molecular changes in the Ts1Cje mouse model of down syndrome. Brain Pathol25, 11–23.
68.
OlssonA, ManzlC, StrasserA, VillungerA (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression?. Cell Death Differ14, 1561–1575.
